Chris Hughes, Columnist

Glaxo Looks Beyond the Lab

She shouldn't forget profit is a byproduct of success in the lab.

July 26, 2017 at 1:46 PM UTC

Chris Hughes is a Bloomberg Opinion columnist covering deals. Previously, he worked for Reuters Breakingviews, the Financial Times and the Independent newspaper.

1501075308_m775811 — Photographer: NORM BETTS

Provide news feedback or report an error

Site feedback:

Take our Survey

This article is for subscribers only.

Emma Walmsley has disappointed the investment bankers. The new CEO of GlaxoSmithKline Plc has reviewed the drugmaker's strategy and decided against big structural changes in favor of just managing things better.

It looks like the company is going to be run for the benefit of its shareholders more than its scientists.